{"id":"adx-038-dose-level-1","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these enzymes, ADX-038 disrupts the PI3K/AKT signaling pathway, which is involved in cell proliferation and survival. This mechanism is thought to contribute to its anti-tumor effects.","oneSentence":"ADX-038 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:03.665Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory chronic lymphocytic leukemia (CLL)"}]},"trialDetails":[{"nctId":"NCT06989359","phase":"PHASE2","title":"Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease","status":"RECRUITING","sponsor":"ADARx Pharmaceuticals, Inc.","startDate":"2025-08-28","conditions":"IgAN, C3G, Complement-mediated Kidney Disease","enrollment":45},{"nctId":"NCT05876312","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ADARx Pharmaceuticals, Inc.","startDate":"2023-08-07","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":445,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ADX-038 Dose Level 1","genericName":"ADX-038 Dose Level 1","companyName":"ADARx Pharmaceuticals, Inc.","companyId":"adarx-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ADX-038 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}